Biotronik announced that since the launch of the ProMRI Eluna pacemaker system in late March 2015, 60 percent of pacing devices sold by the company are approved for use during magnetic resonance imaging (MRI) scans. The announcement was made at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions, May 13-16 in Boston.

The Heart Rhythm Society (HRS) has released a first-of-its-kind expert consensus statement on three specific cardiovascular disorders that also involve the autonomic nervous system. The 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope was written by an international group of experts and published online in HeartRhythm Journal, the official journal of HRS. The expert consensus statement was presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions.

Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from the VENTURE-AF trial. The study explored the potential of once-daily Xarelto (rivaroxaban) as an alternative to vitamin K antagonists (VKA), used to reduce the risk of blood clots, in people with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation, a frequently used interventional procedure to remove abnormal tissue in the heart that is causing the irregular heartbeat. The results were presented at Heart Rhythm 2015, the Heart Rhythm Society's 36th annual scientific sessions, and published in the European Heart Journal.

Acqmap, Acutus, dipole density mapping
Acqmap, Acutus, dipole density mapping
Acqmap, Acutus, dipole density mapping

A preliminary study of a new electrophysiology (EP) mapping system using a specialized intracardiac ultrasound basket catheter for electro-mapping showed it is four times higher resolution than standard voltage mapping. Researchers also said the new mapping modality represents the electromapping data on computed tomography (CT) quality anatomy. The data suggest it may open the possibility to map irregular arrhythmias with more precision. The data was presented at Heart Rhythm Society’s 2015 meeting. 

Medtronic plc announced that its Tyrx Antibacterial Envelope reduces major cardiac device site infections by 80 percent up to 12 months after implantation. These data were presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions in Boston.

Amaranth Medical announced plans to report clinical results from the company's ongoing trial of its second-generation Fortitude sirolimus-eluting bioresorbable scaffold (BRS) at EuroPCR 2015. Juan F. Granada, M.D., executive director and chief innovation officer of the CRF-Skirball Center for Innovation (SCI), will present these updates.

Clinical trial results showed that full-body magnetic resonance imaging (MRI) scans do not affect the Medtronic Evera MRI SureScan implantable cardioverter defibrillator’s (ICD) ability to detect potentially lethal heart rhythms and deliver life-saving therapy. Data were presented during a late-breaking clinical trial session at Heart Rhythm 2015

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now